Literature DB >> 16901394

Novel approaches in allogeneic stem cell transplantation.

Esperanza B Papadopoulos1, Ann A Jakubowski.   

Abstract

Allogeneic transplantation remains an integral part of the management of hematologic malignancies. However, transplant-related mortality, graft-versus-host disease, and disease recurrence continue to be major limitations to successful transplant outcomes and challenges to investigators in the field. Newer approaches have focused on reduction of the intensity of the conditioning regimens, harnessing the antitumor effects of the allograft, and development of adoptive immunotherapy strategies to circumvent the limitations. These developments provide physicians with the ability to tailor transplants to specific patients and their diseases.

Entities:  

Mesh:

Year:  2006        PMID: 16901394     DOI: 10.1007/s11912-006-0054-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  67 in total

Review 1.  Donor lymphocyte infusions.

Authors:  Vincent T Ho; Edwin P Alyea
Journal:  Adv Pharmacol       Date:  2004

2.  T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads.

Authors:  J N Frame; N H Collins; T Cartagena; H Waldmann; R J O'Reilly; B Dupont; N A Kernan
Journal:  Transplantation       Date:  1989-06       Impact factor: 4.939

3.  Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts.

Authors:  N Novitzky; V Thomas; G Hale; H Waldmann
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

4.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

Authors:  Alessandra Recchia; Chiara Bonini; Zulma Magnani; Fabrizia Urbinati; Daniela Sartori; Sara Muraro; Enrico Tagliafico; Attilio Bondanza; Maria Teresa Lupo Stanghellini; Massimo Bernardi; Alessandra Pescarollo; Fabio Ciceri; Claudio Bordignon; Fulvio Mavilio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

5.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Authors:  Ronjon Chakraverty; Karl Peggs; Rajesh Chopra; Donald W Milligan; Panagiotis D Kottaridis; Stephanie Verfuerth; Johanne Geary; Dharsha Thuraisundaram; Kate Branson; Suparno Chakrabarti; Premini Mahendra; Charles Craddock; Anne Parker; Ann Hunter; Geoff Hale; Herman Waldmann; Catherine D Williams; Kwee Yong; David C Linch; Anthony H Goldstone; Stephen Mackinnon
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

6.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

7.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

8.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

Authors:  P Tiberghien; C Ferrand; B Lioure; N Milpied; R Angonin; E Deconinck; J M Certoux; E Robinet; P Saas; B Petracca; C Juttner; C W Reynolds; D L Longo; P Hervé; J Y Cahn
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

9.  Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.

Authors:  S Kreiter; N Winkelmann; P M Schneider; M Schuler; T Fischer; A J Ullmann; C Huber; H G Derigs; K Kolbe
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

10.  A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.

Authors:  Kathleen Cathcart; Javier Pinilla-Ibarz; Tatyana Korontsvit; Joseph Schwartz; Victoriya Zakhaleva; Esperanza B Papadopoulos; David A Scheinberg
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

View more
  1 in total

1.  The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT).

Authors:  Margaret F Bevans; Sandra A Mitchell; Susan Marden
Journal:  Support Care Cancer       Date:  2008-03-06       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.